A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Inclusion Criteria:

1. At least 18 years of age at the time of signing the informed consent form

2. At Screening: AOBP SBP of 140-180 mmHg and AOBP DBP of 65-110 mmHg, or AOBP DBP of 90-110 mmHg

3. 24-hour average ABPM SBP of 130-180 mmHg or 24-hour average ABPM DBP >80 mmHg

4. Taking between 2 and 5 AHT medications, inclusive, at Screening visit.

5. BMI of 18-40 kg/m2 inclusive at Screening

Exclusion Criteria:

1. eGFR <45 mL/min/1.73 m2 at Screening, calculated using the Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) formula

2. Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization

3. Serum sodium <135 mmol/L at Screening

4. History of heart failure, myocardial infarction, stroke, or transient ischemicattack within 6 months prior to Screening.

5. Diabetes mellitus with a glycosylated hemoglobin (HbA1c) >9% (>74.9 mmol/mol) atScreening